(Q46251291)

English

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

1 reference

based on heuristic

inferred from title

author name string

H Landau

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

H Hassoun

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

M A Rosenzweig

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

M Maurer

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

J Liu

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

C Flombaum

6

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

C Bello

7

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

E Hoover

8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

E Riedel

9

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

S Giralt

10

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

R L Comenzo

11

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

publication date

27 September 2012

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

27

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

823-828

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

https://scigraph.springernature.com/pub.10.1038/leu.2012.274

0 references

Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Molecular mechanisms of amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Autologous stem cell transplantation for primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

How I treat amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Antibody-mediated resolution of light chain-associated amyloid deposits.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

21 January 2018

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.274

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2012.274

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/23014566

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46251291&oldid=2102166148"